Loo SY, et al. - Among patients with non-valvular atrial fibrillation (NVAF), particularly in those with chronic kidney disease (CKD), researchers evaluated the effectiveness and safety of novel oral anticoagulants (NOACs) compared with vitamin K antagonists (VKAs). As per results, NOACs were shown to be effective and safe alternatives to VKAs, among patients with NVAF altogether, as well as in patients with NVAF and CKD.